Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide CJ130 with anti-HIV (human immunodeficiency virus)-1 activity and application thereof

A technology for HIV-1 and HIV-1B, which is applied to the anti-HIV-1 active polypeptide CJ130 and its application field, which can solve the problems of toxic side effects and the inability to completely remove the virus.

Active Publication Date: 2015-09-16
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, since this method cannot completely remove the virus, the patient needs to take medicine for life, but long-term medication has serious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide CJ130 with anti-HIV (human immunodeficiency virus)-1 activity and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1, the preparation of polypeptide

[0022] The inventors of the present invention have designed polypeptide CJ130, the amino acid sequence of which is as follows:

[0023] Polypeptide CJ130 (SEQ ID NO: 1 of the Sequence Listing): VWSIVIIEYRKILRQRKIDRRRRRRRRRR.

[0024] Artificially synthesized polypeptide CJ130.

Embodiment 2

[0025] Embodiment 2, the toxicity determination of polypeptide

[0026] 1. Dissolve 1 mg of the polypeptide CJ130 prepared in Example 1 in 20 μl of DMSO, and then perform 2-fold gradient dilution with DMSO to obtain polypeptide dilutions containing different concentrations of the polypeptide.

[0027] 2. Take the white transparent 96-well plate and add the polypeptide dilution prepared in step 1 (1 μl per well).

[0028] 3. Suspend MT-2 cells in RPMI1640 medium containing 10% fetal bovine serum by volume to obtain 1.5×10 5 cells / ml of MT-2 cell suspension.

[0029] 4. Take the MT-2 cell suspension obtained in step 3, add it to the 96-well plate (200 μl per well) that completed step 2, centrifuge briefly, and then 37 ° C, 5% CO 2 Incubate for 72 hours.

[0030] 5. After completing step 4, take the 96-well plate and add 20 μl CellTiter- Luminescent Cell Viability Assay (CellTiter- Luminescence method cell viability detection kit), the luminescence signal was measured by W...

Embodiment 3

[0033] Embodiment 3, the anti-HIV-1 activity determination of polypeptide

[0034]1. Dissolve 1 mg of the polypeptide CJ130 prepared in Example 1 in 20 μl of DMSO, and then perform 2-fold gradient dilution with DMSO to obtain polypeptide dilutions containing different concentrations of the polypeptide.

[0035] 2. Take the white transparent 96-well plate, add the polypeptide dilution prepared in step 1 (1 μl per well)

[0036] 3. Suspend MT-2 cells with RPMI1640 culture medium containing 10% fetal bovine serum by volume percentage to obtain 3.0×10 5 cells / ml of MT-2 cell suspension.

[0037] 4. Adjust the virus concentration in the virus solution of pNL4.3 virus with RPMI1640 culture solution containing 10% fetal bovine serum by volume percentage to obtain a virus dilution solution of 400 TCID50 / ml.

[0038] 5. Mix the MT-2 cell suspension obtained in step 3 with the virus dilution obtained in step 4 in equal volumes, then add the mixed solution to the 96-well plate (200 μl ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a polypeptide CJ130 with anti-HIV (human immunodeficiency virus)-1 activity and an application thereof. The polypeptide is named CJ130 and is shown in a sequence 1 in a sequence table. The invention also discloses the application of the polypeptide CJ130 to preparation of an anti-HIV medicine. The invention also discloses the anti-HIV medicine with the polypeptide CJ130 as the active ingredient. The polypeptide CJ130 is of great value for treatment of AIDS (acquired immunodeficiency syndrome).

Description

technical field [0001] The invention relates to a polypeptide CJ130 with anti-HIV-1 activity and its application. Background technique [0002] Human immunodeficiency virus (Human immunodeficiency virus, HIV) is the pathogen that causes human acquired immunodeficiency syndrome (Acquired immunodeficiency syndrome, AIDS). AIDS has spread rapidly around the world since it was first discovered in the United States in 1981. According to the latest UNAIDS report in July 2014, the number of HIV-infected people in the world has reached 35 million. In 2013, there were 63,498 newly diagnosed HIV-infected people in China, and it is estimated that there are currently 780,000 HIV-infected people living in China. [0003] Currently, Highly Active Anti-Retroviral Therapy (HAART), which uses several antiviral drugs in combination, can greatly reduce the viral load in HIV patients and delay the disease process. However, as of now, AIDS is still incurable. With the widespread use of antire...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/16A61K38/16A61P31/18
CPCA61K38/00C07K14/005C12N2740/00022C12N2740/16322
Inventor 李林李敬云常帅蔡利锋李天一李韩平鲍作义刘永健刘思扬庄道民王晓林
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com